Cucurbitacin Compounds in Cancer Therapeutics

Cucurbitacins are a class of tetracyclic triterpenoids naturally occurring in plants of the Cucurbitaceae family and beyond. Their distinctive polyoxygenated structures confer potent cytotoxic and cytostatic properties against a wide range of malignancies. Preclinical studies have demonstrated that various cucurbitacin analogues disrupt key oncogenic signalling pathways—most notably JAK–STAT3, Wnt/β-catenin, MAPK and PI3K–Akt—leading to cell‐cycle arrest, apoptotic induction and inhibition of migration, invasion and angiogenesis. Advances in network pharmacology have elucidated multiple molecular targets and protein–protein interaction networks, guiding structure–activity optimisation and combination strategies with established chemotherapeutics. Despite challenges such as limited solubility and off‐target toxicity, efforts to enhance bioavailability through novel delivery systems and synthetic modification are under way. The growing body of evidence from in vitro, in vivo and systems‐level analyses positions cucurbitacins as promising lead compounds for next-generation anticancer therapeutics.

Research from Nature Portfolio

Recent studies have shown that Cucurbitacin B exerts nanomolar‐level inhibition of non-small cell lung cancer metastasis by suppressing cell migration, invasion and angiogenesis. Mechanistic investigations revealed downregulation of the canonical Wnt/β-catenin axis both in vitro and in chick embryo and murine tumour models, resulting in disrupted endothelial tube formation and impaired epithelial–mesenchymal transition. Similarly, Cucurbitacin D has been demonstrated to inhibit cervical cancer cell proliferation through G1/S cell-cycle arrest and apoptosis induction. Treatment led to reduced phosphorylation of STAT3, decreased expression of oncogenic targets such as Cyclin D1 and MMP9, and elevated levels of tumour-suppressive microRNAs. In orthotopic xenograft assays, systemic administration of Cucurbitacin D significantly attenuated tumour growth.

Cucurbitacin Compounds in Cancer Therapeutics publication trend

The graph below shows the total number of articles in cucurbitacin compounds in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Cucurbitacins: A family of tetracyclic triterpenoids derived from plants of the Cucurbitaceae family with potent antiproliferative and cytotoxic effects.

Apoptosis: Programmed cell death characterised by caspase activation, chromatin condensation and membrane blebbing, often exploited in anticancer strategies.

Angiogenesis: Formation of new blood vessels from existing vasculature, a process that supports tumour growth and metastasis.

Epithelial–mesenchymal transition (EMT): A cellular programme in which epithelial cells acquire mesenchymal traits, facilitating invasion and dissemination.

Network pharmacology: A systems-level methodology integrating bioinformatics and experimental data to map drug–target interactions and signalling pathway modulation.

References

1. Preliminary investigation of the anti‐colon cancer activity of cucurbitacin C from cucumber: A network pharmacological study and experimental validation. Food Frontiers (2023).
2. Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/β-catenin signaling axis. Scientific Reports (2016).
3. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Scientific Reports (2016).
4. Cucurbitacins - An insight into medicinal leads from nature. Pharmacognosy Reviews (2015).
5. Cucurbitacin E Induces Cell Cycle G2/M Phase Arrest and Apoptosis in Triple Negative Breast Cancer. PLOS ONE (2014).